Futura Medical plc (FAMDF)
USD 0.12
(26.32%)
USD 0.12
(26.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.33 Million GBP | 261.62% |
| 2022 | 1.75 Million GBP | -15.64% |
| 2021 | 2.07 Million GBP | 171.12% |
| 2020 | 766.52 Thousand GBP | -84.19% |
| 2019 | 4.84 Million GBP | 139.32% |
| 2018 | 2.02 Million GBP | 305.8% |
| 2017 | 499.14 Thousand GBP | -41.63% |
| 2016 | 855.17 Thousand GBP | 17.29% |
| 2015 | 729.11 Thousand GBP | 19.94% |
| 2014 | 607.88 Thousand GBP | 27.17% |
| 2013 | 477.99 Thousand GBP | 42.71% |
| 2012 | 334.95 Thousand GBP | 72.66% |
| 2011 | 194 Thousand GBP | 27.63% |
| 2010 | 152 Thousand GBP | -32.14% |
| 2009 | 224 Thousand GBP | 47.37% |
| 2008 | 152 Thousand GBP | -51.75% |
| 2007 | 315 Thousand GBP | 33.47% |
| 2006 | 236 Thousand GBP | -0.42% |
| 2005 | 237 Thousand GBP | 5.33% |
| 2004 | 225 Thousand GBP | 25.0% |
| 2003 | 180 Thousand GBP | -27.13% |
| 2002 | 247 Thousand GBP | -5.73% |
| 2001 | 262 Thousand GBP | -58.41% |
| 2000 | 630 Thousand GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.65 Million GBP | -73.86% |
| 2024 Q2 | 1.65 Million GBP | 0.0% |
| 2023 Q3 | 6.33 Million GBP | 188.77% |
| 2023 Q1 | 2.19 Million GBP | 25.22% |
| 2023 FY | 6.33 Million GBP | 261.62% |
| 2023 Q2 | 2.19 Million GBP | 0.0% |
| 2023 Q4 | 6.33 Million GBP | 0.0% |
| 2022 Q3 | 1.75 Million GBP | 26.23% |
| 2022 Q4 | 1.75 Million GBP | 0.0% |
| 2022 FY | 1.75 Million GBP | -15.64% |
| 2022 Q1 | 1.38 Million GBP | -33.17% |
| 2022 Q2 | 1.38 Million GBP | 0.0% |
| 2021 Q3 | 2.07 Million GBP | 182.63% |
| 2021 Q2 | 735.3 Thousand GBP | 0.0% |
| 2021 Q1 | 735.3 Thousand GBP | -4.07% |
| 2021 FY | 2.07 Million GBP | 171.12% |
| 2021 Q4 | 2.07 Million GBP | 0.0% |
| 2020 Q2 | 950.43 Thousand GBP | 0.0% |
| 2020 FY | 766.52 Thousand GBP | -84.19% |
| 2020 Q1 | 950.43 Thousand GBP | -80.39% |
| 2020 Q3 | 766.52 Thousand GBP | -19.35% |
| 2020 Q4 | 766.52 Thousand GBP | 0.0% |
| 2019 Q2 | 3.53 Million GBP | 0.0% |
| 2019 Q1 | 3.53 Million GBP | 74.54% |
| 2019 FY | 4.84 Million GBP | 139.32% |
| 2019 Q3 | 4.84 Million GBP | 37.12% |
| 2019 Q4 | 4.84 Million GBP | 0.0% |
| 2018 Q2 | 437.58 Thousand GBP | 0.0% |
| 2018 Q3 | 2.02 Million GBP | 362.89% |
| 2018 FY | 2.02 Million GBP | 305.8% |
| 2018 Q1 | 437.58 Thousand GBP | -12.33% |
| 2018 Q4 | 2.02 Million GBP | 0.0% |
| 2017 Q2 | 372.6 Thousand GBP | 0.0% |
| 2017 Q1 | 372.6 Thousand GBP | -56.43% |
| 2017 FY | 499.14 Thousand GBP | -41.63% |
| 2017 Q4 | 499.14 Thousand GBP | 0.0% |
| 2017 Q3 | 499.14 Thousand GBP | 33.96% |
| 2016 Q2 | 708.16 Thousand GBP | 0.0% |
| 2016 FY | 855.17 Thousand GBP | 17.29% |
| 2016 Q4 | 855.17 Thousand GBP | 0.0% |
| 2016 Q3 | 855.17 Thousand GBP | 20.76% |
| 2016 Q1 | 708.16 Thousand GBP | -2.87% |
| 2015 Q1 | 938.13 Thousand GBP | 54.33% |
| 2015 Q4 | 729.11 Thousand GBP | 0.0% |
| 2015 Q3 | 729.11 Thousand GBP | -22.28% |
| 2015 Q2 | 938.13 Thousand GBP | 0.0% |
| 2015 FY | 729.11 Thousand GBP | 19.94% |
| 2014 Q1 | 439.22 Thousand GBP | -8.11% |
| 2014 Q2 | 439.22 Thousand GBP | 0.0% |
| 2014 Q3 | 607.88 Thousand GBP | 38.4% |
| 2014 FY | 607.88 Thousand GBP | 27.17% |
| 2014 Q4 | 607.88 Thousand GBP | 0.0% |
| 2013 Q1 | 285.88 Thousand GBP | -14.65% |
| 2013 FY | 477.99 Thousand GBP | 42.71% |
| 2013 Q3 | 477.99 Thousand GBP | 67.2% |
| 2013 Q2 | 285.88 Thousand GBP | 0.0% |
| 2013 Q4 | 477.99 Thousand GBP | 0.0% |
| 2012 Q4 | 334.95 Thousand GBP | 0.0% |
| 2012 Q2 | 210 Thousand GBP | 0.0% |
| 2012 FY | 334.95 Thousand GBP | 72.66% |
| 2011 Q2 | 146 Thousand GBP | 0.0% |
| 2011 Q4 | 194 Thousand GBP | 0.0% |
| 2011 FY | 194 Thousand GBP | 27.63% |
| 2010 FY | 152 Thousand GBP | -32.14% |
| 2010 Q2 | 151 Thousand GBP | 0.0% |
| 2010 Q4 | 153 Thousand GBP | 0.0% |
| 2009 FY | 224 Thousand GBP | 47.37% |
| 2009 Q4 | 224 Thousand GBP | 0.0% |
| 2009 Q2 | 130 Thousand GBP | 0.0% |
| 2008 Q2 | 260 Thousand GBP | 0.0% |
| 2008 Q4 | 152 Thousand GBP | 0.0% |
| 2008 FY | 152 Thousand GBP | -51.75% |
| 2007 Q4 | 315 Thousand GBP | 0.0% |
| 2007 Q2 | 536 Thousand GBP | 0.0% |
| 2007 FY | 315 Thousand GBP | 33.47% |
| 2006 Q4 | 236 Thousand GBP | 0.0% |
| 2006 FY | 236 Thousand GBP | -0.42% |
| 2006 Q2 | 246 Thousand GBP | 0.0% |
| 2005 Q2 | 201 Thousand GBP | 0.0% |
| 2005 Q4 | 237 Thousand GBP | 0.0% |
| 2005 FY | 237 Thousand GBP | 5.33% |
| 2004 Q2 | 242 Thousand GBP | 0.0% |
| 2004 FY | 225 Thousand GBP | 25.0% |
| 2004 Q4 | 225 Thousand GBP | 0.0% |
| 2003 FY | 180 Thousand GBP | -27.13% |
| 2002 FY | 247 Thousand GBP | -5.73% |
| 2001 FY | 262 Thousand GBP | -58.41% |
| 2000 FY | 630 Thousand GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -95.093% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 88.107% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1403.799% |
| SQZ Biotechnologies Company | 50.03 Million USD | 87.331% |
| Intellipharmaceutics International Inc. | 12 Million USD | 47.209% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 91.252% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 89.258% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -64.602% |
| Marizyme, Inc. | 26.67 Million USD | 76.235% |
| Genus plc | 485 Million USD | 98.693% |
| Pharming Group N.V. | 244.07 Million USD | 97.403% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -215.379% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -151.936% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -66.83% |
| ContraFect Corporation | 32.53 Million USD | 80.512% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -65.625% |
| IMV Inc. | 37.93 Million USD | 83.287% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 46.176% |
| ONE Bio Corp. | 27.49 Million USD | 76.944% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 91.811% |
| Mesoblast Limited | 188.44 Million USD | 96.636% |
| MultiCell Technologies, Inc. | 1617.67 USD | -391792.908% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 92.356% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.522% |
| Neon Bloom, Inc. | 1.22 Million USD | -417.001% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -23.193% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 33.839% |
| Biomind Labs Inc. | 1.49 Million USD | -323.027% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 29.889% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 65.552% |
| Skye Bioscience, Inc. | 14.07 Million USD | 54.95% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -342.13% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -8.505% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4361.476% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -219.967% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 33.028% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3052.178% |
| Accustem Sciences Inc. | 1.07 Million USD | -487.408% |
| EV Biologics, Inc. | 2.11 Million USD | -199.732% |
| Q BioMed Inc. | 8.13 Million USD | 22.051% |
| GB Sciences, Inc. | 5.41 Million USD | -17.018% |
| Alpha Cognition Inc. | 7.16 Million USD | 11.518% |
| CSL Limited | 18.62 Billion USD | 99.966% |
| Agentix Corp. | 2.51 Million USD | -152.515% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 94.66% |
| Enzolytics Inc. | 365.26 Million USD | 98.264% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 90.594% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -655.847% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -10.333% |
| argenx SE | 444.95 Million USD | 98.575% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 91.538% |
| HST Global, Inc. | 593.59 Thousand USD | -967.993% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -269.868% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -403.46% |
| Halberd Corporation | 728.71 Thousand USD | -769.956% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 74.382% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -72.967% |
| Zenith Capital Corp. | 27.56 Thousand USD | -22895.154% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 46.74% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -69.765% |
| AVAX Technologies, Inc. | 3.99 Million USD | -58.737% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -831.142% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -133.79% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2556.37% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | 19.352% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -9372.029% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 87.388% |
| Kadimastem Ltd | 3.5 Million USD | -80.878% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 60.14% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1264.224% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -23009.153% |
| LadRx Corporation | 2.2 Million USD | -188.091% |
| Cell Source, Inc. | 15.8 Million USD | 59.893% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -14083.672% |
| Regen BioPharma, Inc. | 5.45 Million USD | -16.159% |
| Regen BioPharma, Inc. | 5.45 Million USD | -16.159% |
| Affymax, Inc. | 8.87 Million USD | 28.536% |
| Mobile Lads Corp. | 1.31 Million USD | -382.645% |
| Itoco Inc. | 1.65 Million USD | -283.482% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -209.01% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -4.803% |
| International Stem Cell Corporation | 5.27 Million USD | -20.135% |
| CytoDyn Inc. | 127.89 Million USD | 95.043% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -15066.712% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -304.726% |
| Qrons Inc. | 1.48 Million USD | -325.84% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 42.604% |
| SYBLEU INC | 681.41 Thousand USD | -830.351% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -683.826% |
| Rebus Holdings, Inc. | 5.24 Million USD | -20.937% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -3.894% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -913.014% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -37.305% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 84.536% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 71.527% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -213.004% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -15.727% |
| Neutra Corp. | 973.52 Thousand USD | -551.191% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 78.151% |
| PureTech Health plc | 125.58 Million USD | 94.952% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -68.734% |
| IXICO plc | 1.9 Million USD | -233.608% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 69.119% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.864% |
| CSL Limited | 18.62 Billion USD | 99.966% |
| Cellectis S.A. | 249.36 Million USD | 97.458% |